Skip to main content

Table 4 Histone deacetylase inhibitors in clinical trials

From: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Study Agents Other agents Disease Dosage Clinical trails No Pts Response Reference
Vorinostat Idarubicin, Cytarabine untreated AML 500 mg po tid d1-3 Phase II 52 CR/CRp: 80% [37]
Vorinostat decitabine untreated, relapsed AML 400 mg qd, po 1-7d or 1-14d Phase I/II 72 MTD not reached [38]
  1. Abbreviations: CR: complete remission; CRp: CR without platelet recovery; MTD: maximal tolerated dose;